Advertisement

Topics

SMC approves Amgen’s carfilzomib for multiple myeloma treatment

19:00 EDT 8 Aug 2017 | Pharmaceutical Technology

The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Health Service (NHS) Scotland.

Original Article: SMC approves Amgen’s carfilzomib for multiple myeloma treatment

NEXT ARTICLE

More From BioPortfolio on "SMC approves Amgen’s carfilzomib for multiple myeloma treatment"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...